Alliance Global lowered the firm’s price target on Aquestive Therapeutics (AQST) to $9 from $12 and keeps a Buy rating on the shares after the company held its Q4 earnings call, highlighting its New Drug Application resubmission scheduled for Q3 2026 for Anaphylm. This comes following the Complete Response Letter issued by the FDA after June 2025 NDA acceptance. Alliance Global values Anaphylm for anaphylaxis at $7.50/share, Libervant for pediatric epilepsy at 25c/share, the base manufacturing revenues, license/royalties, fees, and other tech at $1/share, and net cash less debt at 25c/share for its $9/share value.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics Amends RTW Deal, Strengthens Financing Outlook
- Aquestive Therapeutics reports Q4 adjusted EPS (15c), consensus (12c)
- Aquestive Therapeutics sees FY26 revenue $46M-$50M, consensus $47.52M
- Aquestive Therapeutics options imply 4.2% move in share price post-earnings
- AQST Earnings Report this Week: Is It a Buy, Ahead of Earnings?